233 related articles for article (PubMed ID: 20354527)
1. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant.
Hu L; McArthur C; Jaffe RB
Br J Cancer; 2010 Apr; 102(8):1276-83. PubMed ID: 20354527
[TBL] [Abstract][Full Text] [Related]
2. Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling.
Hepburn AC; Veeratterapillay R; Williamson SC; El-Sherif A; Sahay N; Thomas HD; Mantilla A; Pickard RS; Robson CN; Heer R
PLoS One; 2012; 7(11):e50690. PubMed ID: 23226356
[TBL] [Abstract][Full Text] [Related]
3. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.
Nakanishi T; Chumsri S; Khakpour N; Brodie AH; Leyland-Jones B; Hamburger AW; Ross DD; Burger AM
Br J Cancer; 2010 Mar; 102(5):815-26. PubMed ID: 20145614
[TBL] [Abstract][Full Text] [Related]
4. A distinct "side population" of cells with high drug efflux capacity in human tumor cells.
Hirschmann-Jax C; Foster AE; Wulf GG; Nuchtern JG; Jax TW; Gobel U; Goodell MA; Brenner MK
Proc Natl Acad Sci U S A; 2004 Sep; 101(39):14228-33. PubMed ID: 15381773
[TBL] [Abstract][Full Text] [Related]
5. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line.
Kondo T; Setoguchi T; Taga T
Proc Natl Acad Sci U S A; 2004 Jan; 101(3):781-6. PubMed ID: 14711994
[TBL] [Abstract][Full Text] [Related]
6. OCT4 accelerates tumorigenesis through activating JAK/STAT signaling in ovarian cancer side population cells.
Ruan Z; Yang X; Cheng W
Cancer Manag Res; 2019; 11():389-399. PubMed ID: 30643464
[TBL] [Abstract][Full Text] [Related]
7. The Cancer Stem Cell Niche in Ovarian Cancer and Its Impact on Immune Surveillance.
Jain S; Annett SL; Morgan MP; Robson T
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920983
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.
Latifi A; Luwor RB; Bilandzic M; Nazaretian S; Stenvers K; Pyman J; Zhu H; Thompson EW; Quinn MA; Findlay JK; Ahmed N
PLoS One; 2012; 7(10):e46858. PubMed ID: 23056490
[TBL] [Abstract][Full Text] [Related]
9. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
[TBL] [Abstract][Full Text] [Related]
12. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
[TBL] [Abstract][Full Text] [Related]
13. Ovarian Cancer Stem Cell Heterogeneity.
Hatina J; Boesch M; Sopper S; Kripnerova M; Wolf D; Reimer D; Marth C; Zeimet AG
Adv Exp Med Biol; 2019; 1139():201-221. PubMed ID: 31134503
[TBL] [Abstract][Full Text] [Related]
14. Endometrial stem/progenitor cells and their role in the pathogenesis of endometriosis.
Cousins FL; O DF; Gargett CE
Best Pract Res Clin Obstet Gynaecol; 2018 Jul; 50():27-38. PubMed ID: 29503126
[TBL] [Abstract][Full Text] [Related]
15. ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance.
Begicevic RR; Falasca M
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29117122
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer stem cells more questions than answers.
Ottevanger PB
Semin Cancer Biol; 2017 Jun; 44():67-71. PubMed ID: 28450177
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer stem cells.
Zeimet AG; Reimer D; Sopper S; Boesch M; Martowicz A; Roessler J; Wiedemair AM; Rumpold H; Untergasser G; Concin N; Hofstetter G; Muller-Holzner E; Fiegl H; Marth C; Wolf D; Pesta M; Hatina J
Neoplasma; 2012; 59(6):747-55. PubMed ID: 22862176
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer development and metastasis.
Lengyel E
Am J Pathol; 2010 Sep; 177(3):1053-64. PubMed ID: 20651229
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
Cheng W; Liu T; Wan X; Gao Y; Wang H
FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
[TBL] [Abstract][Full Text] [Related]
20. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.
Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A
J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
